NanoRepro AG

NN6

Equity

ISIN DE0006577109 / Valor 4691951

Xetra (2024-09-17)

EUR 1.80+2.27%

NanoRepro AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

NanoRepro AG, based in Marburg, Germany, operates in the healthcare sector focusing on the development, manufacturing, and distribution of rapid diagnostic tests and food supplements. Since its public listing in October 2008, the company has positioned itself as a key player in the market for both home and professional use diagnostics. NanoRepro AG's product portfolio includes 24 CE-certified rapid diagnostic tests catering to a range of health concerns, including family planning, preventive healthcare, allergies, and infectious diseases. By offering these self-tests, NanoRepro aims to enhance the accessibility and accuracy of disease detection, facilitating timely health management. The company's commitment to innovation and quality reflects in its comprehensive range of products designed to meet the evolving healthcare needs of consumers worldwide.

Summarized from source with an LLMView SourceSector: Technology

Revenue Decline

In the first quarter of 2023, NanoRepro AG reported a significant decline in revenue, dropping from 38.5 million EUR in the previous year to 3.2 million EUR. This decrease is primarily attributed to the reduced demand for COVID-19 tests post-pandemic.

Core Business Growth

Despite the overall revenue decline, NanoRepro AG experienced notable growth in its core business segments. The company reported a revenue of 2.5 million EUR from self-diagnostic tests and nutritional supplements, marking an 18% increase compared to the previous year.

EBITDA Impact

NanoRepro AG's EBITDA for the first quarter of 2023 fell to -4.4 million EUR from 5.5 million EUR in the previous year. This decline was due to the significant drop in COVID-19 related sales and increased investments in brand building and customer acquisition in the core business.

Investment in Core Segments

The company has been actively investing in its core segments of self-diagnostic tests and nutritional supplements. These investments are aimed at leveraging the momentum gained during the pandemic to strengthen and expand its market presence.

Future Outlook

Looking ahead, NanoRepro AG expects a further increase in revenues from its core business. However, the company anticipates that the overall financial results for the year will still be negative, though improved compared to 2023. The focus remains on sustainable growth and profitability.

Summarized from source with an LLMView Source

Key figures

-32.1%1Y

-80.5%3Y

167%5Y

Performance

44.7%1Y

58.4%3Y

98.1%5Y

Volatility